ANAB - AnaptysBio, Inc. Projected Sales Volume
AnaptysBio, Inc. (ANAB) is developing advanced antibodies to combat atopic dermatitis as it enters the commercialization stage. The projected sales revenue helps assess the company's stability, where the current figure stands at 0.24. The business targets the immunology market, covering both clinics and patients. The monetization model also relies on receiving royalties from global partners for the use of its scientific discoveries.
Analytical breakdowns for AnaptysBio, Inc.
- stock value and consensus price forecast:
- market capitalization statistics:
- book capitalization information:
- debt level and financial liquidity data:
- earnings and market ratios statistics:
ANAB - Net Financial Result|Projected Future Earnings AnaptysBio, Inc.|ANAB - Price to Earnings Ratio|Forward P/E Multiple AnaptysBio|ANAB - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization AnaptysBio Inc|ANAB - Profit before interest, taxes and amortization|Net earnings per share for the last 12 months AnaptysBio|ANAB - Earnings per share for the trailing year|Quarterly EPS earnings growth anaptysbio.com|ANAB - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year AnaptysBio, Inc.
- sales volume and revenue indicators:
Fundamental company valuation:AnaptysBio, Inc. ANAB
Future sales volume represents a projected assessment of aggregate product demand, where analyzing the target volume of marketable products allows for the separation of random market fluctuations from sustainable trends. This metric aggregates expected cash inflows, which is critically important for AnaptysBio, Inc. (ANAB) due to the dependence of revenue on clinical trial results and irregular payments from strategic partners.
Key competitors
Company Projected Revenue argenx SE (ARGX)|biontech.de - Company Revenue Forecast|Projected Sales Volume ABVX (Abivax S.A.)|ADMA Biologics Inc (ADMA) - Company Expected Sales Volume|Protagonist Therapeutics Inc - Projected Sales Volume|IMVT - Projected Sales Volume|Kiniksa Pharmaceuticals (KNSA) - Company Projected Revenue|Company Revenue Forecast GRFS|ADPT (Adaptive Biotechnologies Corporation) - Projected Sales Volume|Projected Sales Volume Celldex Therapeutics Inc|Company Projected Revenue Aurinia Pharma (AUPH)|BCRX: Company Expected Revenue|Vera Therapeutics, Inc. - Company Future Sales Volume|Company Projected Revenue Volume DNTH (dianthustx.com)|PHVS: Company Future Sales Volume|Company Expected Sales Volume AbCellera Biologics Inc.|Tourmaline Corp (TRML) - Company Projected Revenue|PGEN - Company Future Sales|PHAR (Pharming Group N.V.) - Projected Sales Volume|Company Projected Revenue NKTR|Projected Sales Volume UPB|Company Future Sales Zenas Bio|Company Projected Revenue Immunome Corp IMNM|Gossamer Bio Corp. (GOSS) - Company Expected Sales Volume|KALV: Company Future Sales Volume|Company Future Revenue SEPN (septerna.com)|PVLA: Projected Sales Volume|SVRA - Company Future Sales|Company Projected Revenue Rigel Pharmaceuticals Inc|Company Revenue Forecast ATXS (Astria Corp)|Projected Sales Volume ENGN|Company Future Sales Volume rapt.com RAPT|Aerovate Therapeutics - Company Future Sales Volume|Company Future Sales Aclaris Therapeutics Inc. (ACRS)|Kyverna - Projected Sales Volume|TLSA - Projected Sales Volume|Cabaletta Bio, Inc. (CABA) - Company Projected Revenue|Company Revenue Forecast VTYX|THTX (Theratechnologies) - Projected Sales Volume|Projected Sales Volume Avalo Therapeutics, Inc.|Projected Sales Volume ELDN|Company Projected Revenue AGEN (Agenus, Inc)|Company Projected Revenue Climb Bio Inc CLYM|ZURA (zurabio.com) - Company Expected Revenue|aTyr Pharma - Projected Sales Volume|Company Future Revenue ADAG (Adagene)|IMA: Projected Sales Volume|Shattuck Labs (STTK) - Projected Sales Volume|Company Projected Revenue Equillium Inc|CNTB: Company Future Revenue|Company Projected Revenue Immunic, Inc. (IMUX)|Company Future Sales Volume atarabio.com ATRA|Projected Sales Volume IFRX (InflaRx)|Projected Sales Volume X4 Pharmaceuticals, Inc XFOR|ACET: Company Future Sales Volume|Company Future Revenue CELU (Celularity Inc.)|INMB: Projected Sales Volume|BRNS - Company Future Sales|Company Projected Revenue Kezar Life Sciences, Inc|Company Future Sales Volume SAB Biotherapeutics Inc (SABS)|Company Projected Revenue Akari Therapeutics (AKTX)|Company Future Sales Volume enlivex.com ENLV|Q32 Bio - Company Future Sales Volume|Projected Sales Volume GeoVax Labs GOVX|EDSA - Company Projected Revenue|IBIO (iBio Corporation) - Company Revenue Forecast|CARM: Projected Sales Volume|Company Expected Sales Volume xtlbio.com (XTLB)|BOLT (Bolt Biotherapeutics Inc.) - Projected Sales Volume|Projected Sales Volume HCW Biologics Inc|Company Projected Revenue Aptevo Therapeutics (APVO)|aimimmuno.com - Company Revenue Forecast|Projected Sales Volume ADTX (Aditxt, Inc.)|Projected Sales Volume gribio.com GRI|XRTX - Company Projected Revenue|Company Expected Revenue HIND|REVB (Revelation Bio) - Company Future Sales Volume|INDP: Company Projected Revenue Volume|Company Future Sales Volume SCNI|Company Expected Sales Volume CalciMedica Corp CALI|Company Projected Revenue Affimed (AFMD)|Company Future Sales allakos.com|Projected Sales Volume HOOK (HOOKIPA Pharma)|IGM Biosciences Inc. - Company Projected Revenue|iTeos Therapeutics - Projected Sales Volume|Company Future Sales oceanbiomedical.com OCEA|TC BioPharm (TCBP) - Company Projected Revenue|Company Expected Sales Volume Third Harmonic Bio Inc. (THRD)
